487 related articles for article (PubMed ID: 27956320)
21. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.
Madeira I; Terris B; Voss M; Denys A; Sauvanet A; Flejou JF; Vilgrain V; Belghiti J; Bernades P; Ruszniewski P
Gut; 1998 Sep; 43(3):422-7. PubMed ID: 9863490
[TBL] [Abstract][Full Text] [Related]
22. A non-functioning pancreatic neuroendocrine tumour: a case report.
Rosiek V; Kunikowska J; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):59-64. PubMed ID: 22378100
[TBL] [Abstract][Full Text] [Related]
23. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
[TBL] [Abstract][Full Text] [Related]
25. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
[TBL] [Abstract][Full Text] [Related]
27. Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection.
Fossmark R; Balto TM; Martinsen TC; Grønbech JE; Munkvold B; Mjønes PG; Waldum HL
Scand J Gastroenterol; 2019 Aug; 54(8):1003-1007. PubMed ID: 31368380
[No Abstract] [Full Text] [Related]
28. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
29. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
31. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H; Honma Y; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Kato K; Fukuda T; Boku N
Invest New Drugs; 2019 Jun; 37(3):573-578. PubMed ID: 30267338
[TBL] [Abstract][Full Text] [Related]
32. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
33. Surgical resection for duodenal neuroendocrine neoplasia: Outcome, prognostic factors and risk of metastases.
Nießen A; Bergmann F; Hinz U; Schimmack S; Hackert T; Büchler MW; Strobel O
Eur J Surg Oncol; 2020 Jun; 46(6):1088-1096. PubMed ID: 32088004
[TBL] [Abstract][Full Text] [Related]
34. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
[TBL] [Abstract][Full Text] [Related]
36. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.
Del Prete M; Di Sarno A; Modica R; Lassandro F; Giorgio A; Bianco A; Muto M; Gasperi M; Del Prete F; Colao A; Montesarchio V; Faggiano A;
J Endocrinol Invest; 2017 Dec; 40(12):1373-1380. PubMed ID: 28667452
[TBL] [Abstract][Full Text] [Related]
37. [The clinical characteristic of 43 cases of neuroendocrine tumors with liver metastases].
Li P; Yang XO; Qian JM
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):289-93. PubMed ID: 22781949
[TBL] [Abstract][Full Text] [Related]
38. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study.
Le Roux C; Lombard-Bohas C; Delmas C; Dominguez-Tinajero S; Ruszniewski P; Samalin E; Raoul JL; Renard P; Baudin E; Robaskiewicz M; Mitry E; Cadiot G;
Dig Liver Dis; 2011 Oct; 43(10):828-33. PubMed ID: 21641888
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
Poultsides GA; Huang LC; Chen Y; Visser BC; Pai RK; Jeffrey RB; Park WG; Chen AM; Kunz PL; Fisher GA; Norton JA
Ann Surg Oncol; 2012 Jul; 19(7):2295-303. PubMed ID: 22396008
[TBL] [Abstract][Full Text] [Related]
40. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
